Get the Stockscreener App
1.75
1.74%
0.03
Protalix BioTherapeutics Inc. stock is traded at $1.75, with a volume of 580.03K.
It is up +1.74% in the last 24 hours and down -25.21% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$1.72
Open:
$1.71
24h Volume:
580.03K
Relative Volume:
0.72
Market Cap:
$140.74M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
35.00
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
-4.37%
1M Performance:
-25.21%
6M Performance:
+9.37%
1Y Performance:
+7.36%
1-Day Range:
$1.69
$1.78
1-Week Range:
$1.65
$1.85
52-Week Range:
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.75 | 138.32M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
Why analysts recommend Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Will Protalix BioTherapeutics Inc. (PBDA) stock rise with strong economy2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikes2025 Short Interest & Growth Oriented Trading Recommendations - Newser
Why global investors buy Protalix BioTherapeutics Inc. (DE) stockMarket Sentiment Summary & Technical Entry and Exit Tips - Newser
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunity - Newser
Will Protalix BioTherapeutics Inc. (DE) stock split increase liquidityJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
Why Protalix BioTherapeutics Inc. (DE) stock attracts wealthy investors2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Is Protalix BioTherapeutics Inc. (DE) stock supported by strong fundamentals2025 Volume Leaders & Technical Confirmation Trade Alerts - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock behaves under inflation pressure2025 Bull vs Bear & Verified Entry Point Detection - Newser
How Protalix BioTherapeutics Inc. (PBDA) stock compares with top peersJuly 2025 Selloffs & Short-Term High Return Ideas - Newser
Will Protalix BioTherapeutics Inc. (DE) stock test record highs in 2025Weekly Trade Recap & Risk Controlled Swing Alerts - Newser
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Sentiment Watch: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsCPI Data & AI Based Buy and Sell Signals - BỘ NỘI VỤ
Protalix BioTherapeutics Inc. R (PBDA.F) Q1 FY2025 earnings call transcript - Yahoo Finance
Protalix BioTherapeutics Inc. R (PBDA.F) Q2 FY2025 earnings call transcript - Yahoo Finance
Research Analysts Set Expectations for PLX FY2025 Earnings - Defense World
HC Wainwright Lowers Protalix BioTherapeutics (NYSE:PLX) Price Target to $12.00 - Defense World
PLX Analyst Forecasts - Quiver Quantitative
Protalix BioTherapeutics (PLX) Price Target Lowered by HC Wainwr - GuruFocus
HC Wainwright & Co. Maintains Protalix BioTherapeutics (PLX) Buy Recommendation - Nasdaq
Can Protalix BioTherapeutics Inc. (PBDA) stock sustain double digit ROEJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Is Protalix BioTherapeutics Inc. stock undervalued vs historical averagesQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
What RSI levels show for Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Fed Impact & Advanced Technical Signal Analysis - newser.com
Zacks Small Cap Has Bearish Outlook for PLX FY2025 Earnings - Defense World
Will Protalix BioTherapeutics Inc. stock maintain dividend yieldJuly 2025 Decliners & Daily Entry Point Alerts - newser.com
PLX: Protalix Seeks Re-Examination of CHMP Opinion - MSN
How to integrate Protalix BioTherapeutics Inc. into portfolio analysis toolsEarnings Summary Report & Safe Capital Growth Stock Tips - newser.com
[Form 4] Protalix BioTherapeutics, Inc. Insider Trading Activity - Stock Titan
Real time scanner hits for Protalix BioTherapeutics Inc. explained2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Will breakout in Protalix BioTherapeutics Inc. lead to full recovery2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
How Protalix BioTherapeutics Inc. stock reacts to job market dataWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Protalix BioTherapeutics Inc (PLX) - Setenews
Will Protalix BioTherapeutics Inc. stock benefit from AI adoptionDip Buying & Verified Momentum Stock Watchlist - newser.com
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):